Tech Company Financing Transactions
Kuria Therapeutics Funding Round
Kuria Therapeutics closed a funding round on 9/9/2022. Investors included private investors.
Transaction Overview
Company Name
Announced On
9/9/2022
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends intends to use the funds to advance R&D activities to support ongoing preclinical development activities ahead of a planned Series A raise. This round will support selection of a lead ophthalmic formulation, preclinical proof-of-concept studies, and initiation of key manufacturing activities for IND-enabling work and future clinical studies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6834 Cantrell Rd. 1651
Little Rock, AR 72207
USA
Little Rock, AR 72207
USA
Phone
Undisclosed
Website
Email Address
Overview
Kuria Therapeutics is developing a novel topical Nrf2 activator for important diseases of the eye and skin. Our lead program (KTX-1161) targets the corneal endothelium, where there is strong biologic evidence that activation of Nrf2 can treat and prevent diseases with high unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keith Ward
Chief Medical Officer
Brooks Gentry
Chief Operating Officer
Misty Stevens
Chief Technical Officer
Ralph Henry
VP - Bus. Development
David Flory
Browse more venture capital transactions:
Prev: 9/9/2022: Millie venture capital transaction
Next: 9/9/2022: Jobbatical venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs